Sign In
Buy BIIB
$195.96
+7.13 (+3.78%)
At Close: Jun 03, 2026
CAMBRIDGE, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that the European Commission (EC) has granted marketing authorization for ZURZUVAE® (zuranolone) to treat p
Biogen Inc. (BIIB) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
06:51pm, Monday, 08'th Sep 2025
Biogen Inc. (NASDAQ:BIIB ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 10:45 AM EDT Company Participants Christopher Viehbacher - President, CEO & Director Conference Cal
C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration
07:00am, Thursday, 04'th Sep 2025
WATERTOWN, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science,
Global drugmakers rush to boost US presence as tariff threat looms
02:09pm, Wednesday, 03'rd Sep 2025
Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.
LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start to help patients and care partners treat this progressive
BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with R
– Durable reductions in seizures and continuing improvements in cognition and behavior through 3 years in patients who continued to receive zorevunersen in the open-label extension studies –
These Stocks Are Moving the Most Today: Nvidia, Biogen, NIO, Spirit Aviation, and More
04:54am, Tuesday, 02'nd Sep 2025
Companies on the move in today's trading.
Biogen Secures FDA Nod for Subcutaneous Maintenance Dosing of Leqembi
11:36am, Monday, 01'st Sep 2025
BIIB wins FDA approval for Leqembi Iqlik, a fast, subcutaneous option for early Alzheimer's patients transitioning from IV infusions.
US FDA approves injectable version of Eisai-Biogen's Alzheimer's drug
05:08pm, Friday, 29'th Aug 2025
The U.S. Food and Drug Administration has approved an injectable version of Eisai and Biogen's Alzheimer's disease drug Leqembi, the companies said on Friday, allowing for an easier treatment option f
FDA Approves Biogen, Eisai's Highly Anticipated Alzheimer's Treatment
05:00pm, Friday, 29'th Aug 2025
Biogen and Eisai won Food and Drug Administration approval of an at-home shot version of their Alzheimer's treatment Leqembi.
LEQEMBI IQLIK is the first and only anti-amyloid treatment to offer an at-home injection to help patients and care partners continue to treat this progressive, relentless disease after initial treatme
FDA recommends more monitoring of Alzheimer's patients on Biogen's drug Leqembi
02:16pm, Thursday, 28'th Aug 2025
The U.S. Food and Drug Administration said on Thursday it is recommending an additional, earlier magnetic resonance imaging monitoring prior to the third infusion for patients with Alzheimer's disease
BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with R
– 3-year data from open-label extension (OLE) studies demonstrate the potential for disease modification with durable seizure reductions and improvements in cognition and behavior on top of standard
